LFVN Institutional Ownership

LIFEVANTAGE CORP

Latest close $6.70 as of Aug 5, 2026

LFVN institutional ownership at a glance

Follow LIFEVANTAGE CORP institutional ownership through recent Schedule 13G and 13D filings. Compare reported shares, ownership percentages, filing dates, and changes in beneficial ownership over time.

Latest filing: BlackRock filed Schedule 13G amendment on Jul 29, 2026, reporting 229.4K shares and 12.00% beneficial ownership.

Browse recent ownership filings How Schedule 13G works Why a 13G is not a trade report

How to read Schedule 13 ownership changes

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.

Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.

Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

This gauge summarizes recent agreement across tracked institutional activity.

Latest filing Jul 29, 2026

Public consensus preview Reduction leaning 30/100 institutional research score

1 tracked institution Latest filing Jul 29, 2026

1 reducing across 1 comparable institution.

Accumulating0

Unchanged0

Reducing1

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$3.90 52-week high$15.00

Latest close $6.70 25.2% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Jun 30, 2026

BlackRock Jul 29, 2026 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists, portfolio tools, and the first live gauge on the default tracker. Investor or Pro reveals research gauges across tracker views and unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 3 filing(s)

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
BlackRock CIK0002012383	Jun 30, 2026 observed Jul 29, 2026 filed · 29d Schedule 13G amendment	Reported reduction	229.4K -502.6K	12.00% 0.00 pts	$6.24	$6.35	$6.70
BlackRock CIK0002012383	Sep 30, 2025 observed Oct 17, 2025 filed · 17d Initial Schedule 13G	Initial Schedule 13G	732.1K	12.00%	$9.73	$8.81	$6.70
BlackRock CIK0002012383	Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence	Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal.	200.2K				$6.70

Explore more institutional activity

Related research

Compare LFVN with other securities showing similar institutional activity or recent accumulation across several tracked institutions.

Similar institutional activity

REPL Replimune Group, Inc. 30/100 Reduction leaning CPRI CAPRI HOLDINGS LTD 30/100 Reduction leaning OCFC OCEANFIRST FINANCIAL CORP 30/100 Reduction leaning PCRX Pacira BioSciences, Inc. 30/100 Reduction leaning

Recent multi-institution accumulation

OCGN OCUGEN INC 2 accumulating Aug 7, 2026 DNTH Dianthus Therapeutics, Inc. /DE/ 2 accumulating Aug 7, 2026 SRPT Sarepta Therapeutics, Inc. 2 accumulating Aug 7, 2026 RARE ULTRAGENYX PHARMACEUTICAL IN 2 accumulating Aug 7, 2026